FDA Rejects Cingulate's Lead ADHD Drug, Jeopardizing Company's Future
CING sits 20% above its 52-week low of $3.16 on elevated volume (3.7× avg).
Summary
The FDA has declined to approve Cingulate's lead ADHD drug candidate, a devastating blow for the company. This decision follows earlier disclosures of FDA manufacturing observations and comes as Cingulate has been aggressively raising capital to fund pre-commercialization costs, as detailed in its recent 10-Q and 10-K which included a going concern warning. The rejection of its primary asset severely jeopardizes the company's future and its ability to secure further financing.
At the time of this announcement, CING was trading at $3.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $47.8M. The 52-week trading range was $3.16 to $11.89. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.